Corbin Davis


Authored Items

Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery

May 2018, Vol 8, No 5 - 2018 Head and Neck Cancers Symposium

A shorter interval from surgery to the start of radiation therapy has been linked to improved survival in patients with head and neck cancers, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Results of a retrospective analysis showed that patients who received radiation within 42 days of surgery had a median overall survival (OS) of 10.5 years versus 8.2 years for those who received radiation 43 to 49 days after surgery. Moreover, when radiation was delayed by ≥50 days postsurgery, the median OS dropped to 6.5 years. The data also demonstrated improved OS for patients who received accelerated versus standard fractionated therapy, the investigators noted. [ Read More ]

Cabozantinib Active as First-Line Treatment of Differentiated Thyroid Cancer

May 2018, Vol 8, No 5 - 2018 Head and Neck Cancers Symposium

Results from a phase 2 clinical trial have shown that cabozantinib (Cometriq) is active in radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Cabozantinib induction therapy resulted in a 54% response rate and an 80% clinical benefit, meeting the study primary end point. The treatment was also well-tolerated, with mostly grade 1 and 2 adverse events. [ Read More ]

Treatment Considerations for Relapsed or Refractory Multiple Myeloma

March 2018, Vol 8, No 3 - Hematologic Malignancies

Despite major advances in treatment interventions, multiple myeloma remains incurable in the majority of patients, and relapse is an expected part of the disease course. At the 2017 NCCN Hematologic Malignancies Congress, Natalie S. Callander, MD, a hematologist at the University of Wisconsin Carbone Cancer Center, Madison, outlined issues in the management of relapsed or refractory multiple myeloma. [ Read More ]

Treating Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

December 2017, Vol 7, No 12 - NCCN Hematologic Malignancies News

San Francisco, CA—Recent advances in the treatment of patients with multiple myeloma have dramatically altered the trajectory of the disease, as providers now have several efficacious agents in various drug classes at their disposal. At the 2017 NCCN Hematologic Malignancies Congress, Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN, provided management strategies for newly diagnosed multiple myeloma, including the role of autologous stem-cell transplant (ASCT) and posttransplant maintenance therapy. [ Read More ]

2017 the Year of Acute Myeloid Leukemia: New Targeted Therapies

December 2017, Vol 7, No 12 - NCCN Hematologic Malignancies News

San Francisco, CA—After nearly 40 years of negligible drug development, in 2017 the FDA approved 4 drugs for acute myeloid leukemia (AML). These novel therapies have been shown to decrease relapse rates, improve response rates in patients with specific mutations, and reduce short- and long-term adverse reactions associated with current treatment strategies. [ Read More ]

Survivorship Care: Managing Long-Term Side Effects of Lymphoma Treatment

December 2017, Vol 7, No 12 - Survivorship

San Francisco, CA—With 5-year survival rates for Hodgkin lymphoma and non-Hodg­kin lymphoma (NHL) at 86% and 71%, respectively, the number of lymphoma survivors is on the rise, but achieving long-term quality of life after treatment has ended remains a challenge. Data presented at the 2017 NCCN Hematologic Malignancies Congress reveal that treatment-related side effects cause long-term metabolic, endocrine, physical, and mental alterations that impair functional capacity. [ Read More ]